ARTICLE | Product Development

Trio of tactics to target COVID-19 hyperinflammation

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

April 21, 2020 1:32 AM UTC
Updated on Apr 21, 2020 at 1:39 AM UTC

Three companies announced COVID-19 programs Monday aimed at blocking the excessive inflammatory response seen in severe cases. Alexion unveiled a global program for its C5 inhibitor Ultomiris, while 4D pharma moved its live biotherapeutic therapy closer to the clinic, and Cyclacel partnered with the University of Edinburgh to test its pair of apoptosis regulators.

The programs join the more than 150 therapeutics in the clinic for COVID-19 (see “Daily Chart”)...